Background: Severe hematological toxicity has been frequently observed during amrubicin monotherapy for patients with lung cancer despite the favorable anti-tumor response. The purpose of this retrospective study was to identify pretreatment factors associated with severe hematological toxicity. Methods: The medical records of lung cancer patients treated with amrubicin monotherapy were reviewed, and univariate and multivariate analyses were conducted. Results: From January 2003 to December 2006, the medical records of 103 patients were extracted. Grade 4 neutropenia was frequently observed in females (male, 66% and female, 90%, P ¼ 0.036 in a univariate analysis). In a multivariate analysis, female gender (P ¼ 0.019), body weight loss (P ¼ 0.021) and amrubicin dose (P ¼ 0.028) were significantly correlated with Grade 4 neutropenia. Conclusion: Gender could be considered as one of the important predictive factors associated with Grade 4 neutropenia in patients receiving amrubicin monotherapy.
INTRODUCTION
Amrubicin (AMR), an anthracycline derivative, is a completely synthetic agent developed in Japan. AMR has an active metabolite, amrubicinol (AMR-OH), which is distinguishable from other anthracyclines discovered through natural products. AMR-OH has been designed to have an antitumor activity that is 5 -200 times greater than that of its parent compound. This pharmacological property produces a more potent antitumor activity than doxorubicin (1) .
The standard treatment procedure for AMR monotherapy is a 5 min intravenous administration with a recommended dose of 45 mg/m 2 on three consecutive days every 3 -4 weeks. In previous phase II trials of AMR monotherapy for lung cancer, the response rates were reported to be 76 and 28% among patients with small cell lung cancer and non-small cell lung cancer, respectively (2, 3) . The dose-limiting toxicity of AMR is neutropenia, and severe hematological toxicities are frequently observed. The incidence of Grade !3 neutropenia, leukopenia, thrombocytopenia and anemia were reported to be 72 -85, 52 -54, 15 -29 and 21 -31%, respectively (2 -4) .
In a previous pharmacokinetics (PK) analysis of AMR, exposure to AMR and AMR-OH contributed to the severe hematological toxicity of AMR (5, 6) , while the existence of predictive factors of severe hematological toxicity associated with AMR remained unclear. The purpose of this study was to identify pretreatment factors associated with severe hematological toxicity of AMR monotherapy.
PATIENTS AND METHODS

PATIENTS
The medical records of consecutive lung cancer patients treated with AMR monotherapy between January 2003 and December 2006 at the National Cancer Center Hospital were retrospectively reviewed. The following information was extracted: gender, age, histology, performance status (PS), body weight loss in the preceding 6 months, sites of metastasis, previous treatment, complete blood cell counts, chemistry analyses including hepatic and renal functions and treatment delivery during AMR treatment. This study was approved by the institutional review board of the National Cancer Center Hospital. 
STATISTICAL METHODS
Neutropenia, leukopenia, thrombocytopenia (Grade 4 or less) and anemia (Grade 3 or less) in the first cycle were stratified into two groups. To evaluate the relationship between each patient characteristic and the severity of the hematological toxicities, univariate and multivariate analyses were performed using the x 2 test or Fisher's exact test and logistic regression, respectively. A two-sided P value of ,0.05 was considered to indicate statistical significance. All statistical analyses were performed using JMP version 8 software (SAS Institute Japan, Tokyo, Japan). 
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RESULTS
PATIENT CHARACTERISTICS AND TREATMENT DELIVERY
Between January 2003 and December 2006, 103 consecutive patients were identified for this retrospective analysis. The majority of the patients had a good PS with a median age of 64 (range: 25 -78) years; and 81% were male, and 83% were diagnosed as small cell carcinoma. All the patients, except for one patient, had previously received platinum-based chemotherapy, and 41% of them had received two or more regimens (Table 1) . A total of 381 cycles of AMR monotherapy had been delivered (median: 4, range: 1 -10). Thirty-six of the 86 patients who received a second cycle of treatment required a dose reduction because of hematological toxicities (Fig. 1) .
TOXICITIES
Grade 4 neutropenia, leukopenia and thrombocytopenia were observed in 71, 25 and 9% of the 103 patients, respectively. Grade 4 neutropenia was frequently observed in female (male/female: 66/90%). Febrile neutropenia was observed in 24% of the patients, and these patients also had Grade 4 neutropenia (Table 2) . Treatment-related death, due to pneumonia with Grade 4 neutropenia, was observed in one patient. The ANC value -time profiles for all the patients are shown in Fig. 2 . This figure shows that the nadir ANC occurred around the 12-15th day of treatment.
RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS AND HEMATOLOGICAL TOXICITY
In a univariate analysis, female gender (P ¼ 0.036) and body weight loss !5% in the preceding 6 months (P ¼ 0.048) were significantly correlated with Grade 4 neutropenia ( Table 3 ). In addition to female gender (P ¼ 0.014) and body weight loss (P ¼ 0.014), the dose of AMR (P ¼ 0.017) was also significantly correlated with Grade 4 neutropenia in a multivariate analysis (Table 3 ). Grade 4 leukopenia was significantly correlated with body weight loss (odds ratio: 0.11, confidence interval: 0.03 -0.40, P , 0.001) and the dose of AMR (odds ratio: 0.28, confidence interval: 0.08 -0.88, P ¼ 0.028) in a multivariate analysis; Grade 4 thrombocytopenia and !Grade 3 anemia were not correlated with any pretreatment factors. 
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The relationship between gender and the percentage decrease in ANC is shown in Fig. 3 . A gender difference was observed in the percentage decrease in the blood counts or level [male vs. female (ANC: 87 vs. 95%, P , 0.001; WBC: 72 vs. 79%, P ¼ 0.009; PLT: 58 vs. 70%, P ¼ 0.043; HGB level: 16 vs. 19%, P ¼ 0.047)]. Body weight loss also influenced the percentage decrease in the blood counts or level [!5 vs. ,5% (ANC: 89 vs. 75%, P , 0.001; WBC: 71 vs. 83%, P , 0.001; PLT: 59 vs. 69%, P ¼ 0.041)] except for HGB level (!5 vs. ,5%; 7.6 vs. 6.8%, P ¼ 0.911). There were no significant differences in any other factors with regard to the percentage decrease in the blood counts or level. 
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DISCUSSION
We conducted a retrospective analysis to identify pretreatment factors associated with severe hematological toxicity of AMR monotherapy. As a result, female gender, body weight loss in the preceding 6 months and the AMR dose were found to be significantly correlated with Grade 4 neutropenia. Female gender and body weight loss were also found to be significantly correlated with febrile neutropenia, which is clinically important (data not shown). This is the first report concerning a gender difference in the hematological toxicity of AMR. Chemotherapy-related toxicities are reportedly more severe in female, although the mechanisms for this gender difference remain unknown. Among antitumor agents, a gender difference has only been reported for fluorouracil (7) . Although a detailed analysis has not been reported, gender differences in metabolic enzyme activity could impact differences in both PK and toxicities (8) . AMR is metabolized to its active metabolite AMR-OH by carbonyl reductase (CBR) (9) , and a gender difference in the metabolic activity of CBR had been reported (10, 11) . This gender difference in CBR activity could influence the PK of AMR-OH and hematological toxicities. Body weight loss in the preceding 6 months was associated with severe hematological toxicity of AMR. Body weight loss, known as a poor prognostic factor in lung cancer, could affect a patient's ability to regain an acceptable blood count between chemotherapy cycles and is associated with an increased incidence of anemia during treatment for lung cancer (12, 13) .
In addition to gender and body weight loss, the dose of AMR also had a significant impact in this study. The doselimiting toxicity of AMR is neutropenia, therefore, it could be considered reasonable as one of the important predictive factors in AMR toxicities.
This study had some limitations because of the nature of retrospective studies, the small sample size and the small number of female patients. A prospective study is needed to confirm the association between gender differences in CBR activity, the PK of AMR-OH and hematological toxicity.
Although AMR has a potent antitumor activity, severe hematological toxicity is frequently observed. To reduce severe toxicity, further investigation is warranted. We are currently conducting a prospective PK, pharmacodynamics and pharmacogenomics study of AMR. 
